{"id":49891,"date":"2025-12-03T22:24:33","date_gmt":"2025-12-03T14:24:33","guid":{"rendered":"https:\/\/flcube.com\/?p=49891"},"modified":"2025-12-03T22:24:34","modified_gmt":"2025-12-03T14:24:34","slug":"china-drug-price-registration-system-launches-with-first-batch-of-10-products","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49891","title":{"rendered":"China Drug-Price Registration System Launches with First Batch of 10 Products"},"content":{"rendered":"\n

China\u2019s Drug Price Registration System<\/strong> officially launched today with the first batch of 10 drug products<\/strong> from nine pharmaceutical companies<\/strong>, including China Meheco, Tong Ren Tang, BeOne, Akeso, Yifan Pharma, Roche Pharma, JW Therapeutics, IASO Bio, and Hengrui Pharmaceuticals. The system enables voluntary price registration based on company development needs and establishes a dual pricing mechanism for pharmaceuticals.<\/p>\n\n\n\n

First Batch Registrants & System Features<\/h2>\n\n\n\n
Registrant Count<\/th>Companies<\/th>System Framework<\/th><\/tr><\/thead>
9 Companies<\/strong><\/td>China Meheco, Tong Ren Tang, BeOne, Akeso, Yifan Pharma, Roche Pharma, JW Therapeutics, IASO Bio, Hengrui Pharmaceuticals<\/td>Voluntary Registration<\/strong>: Companies declare prices based on development needs<\/td><\/tr>
10 Products<\/strong><\/td>First batch of drug products<\/td>Price Authenticity<\/strong>: Companies responsible for declared price veracity<\/td><\/tr>
Operating Unit<\/strong><\/td>Government agency<\/td>Non\u2011Interference<\/strong>: Accepts applications without influencing specific price levels<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Dual Pricing Mechanism & International Competitiveness<\/h2>\n\n\n\n
Pricing System<\/th>Purpose<\/th>Key Characteristics<\/th><\/tr><\/thead>
Public Market List Price<\/strong><\/td>Transparent, comparable pricing for international comparison<\/td>Voluntarily registered by companies; represents true market pricing outside insurance settlements<\/td><\/tr>
Confidential Insurance Payment Price<\/strong><\/td>Lower settlement price for domestic medical insurance<\/td>Independent from list price; does not change insured\/uninsured patient price levels<\/td><\/tr>
International Practice<\/strong><\/td>Strengthens Chinese pharma companies’ ability to participate in global competition<\/td>Two independent price sets, common in developed markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Implications<\/h2>\n\n\n\n